CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

48.96 -0.43 (-0.87%)

Delayed Quote Updated: 1:42 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

37 38 Next >

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

March 20, 2024

Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel

Via MarketBeat

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today ↗

March 19, 2024

Via Benzinga

Is It Too Late to Buy CRISPR Therapeutics Stock? ↗

March 16, 2024

The biotech has been making a lot of noise since late last year.

Via The Motley Fool

The 3 Most Undervalued Cathie Wood Stocks to Buy in March 2024 ↗

March 15, 2024

These undervalued Cathie Wood stocks capture her favorite trends and remain undervalued even as the wider tech sector surge.

Via InvestorPlace

7 Biotech Stocks to Buy as Sector Rotation Ramps Up ↗

March 13, 2024

With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.

Via InvestorPlace

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today ↗

February 23, 2024

Via Benzinga

Smart Money Is Betting Big In CRSP Options ↗

February 22, 2024

Via Benzinga

Cathie Wood's Ark Invest Keeps Dumping Coinbase Shares Amid Bitcoin, Crypto Buzz ↗

March 12, 2024

On Tuesday, Cathie Wood-led Ark Invest made a significant move by offloading a substantial number of shares in Coinbase Global Inc (NASDAQ:COIN), despite Bitcoin (CRYPTO: BTC) reaching new

Via Benzinga

It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility ↗

March 11, 2024

Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23.

Via Talk Markets

The Top 3 Biotech Stocks to Buy in March 2024 ↗

March 06, 2024

Although the biotech sector puts the benefits and risks in plain sight, three top biotech stocks to buy shine for investors.

Via InvestorPlace

Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments

March 06, 2024

Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place

Via MarketBeat

Here's Why CRISPR Therapeutics Stock Climbed 34% in February ↗

March 05, 2024

The biotech company keeps moving closer to bringing its promising first gene therapy to market.

Via The Motley Fool

ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential ↗

March 04, 2024

Here are three ChatGPT stock predictions for the most unpredictable of biotech stocks that might just have 10x potential.

Via InvestorPlace

Topics Artificial Intelligence

MarketBeat Week in Review – 2/26 - 3/1

March 02, 2024

As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest

Via MarketBeat

Topics Economy Stocks

CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst ↗

February 29, 2024

This company's fortunes are likely to improve, and soon.

Via The Motley Fool

A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now ↗

February 29, 2024

The futures for these two beaten-down stocks could be brighter than their recent pasts.

Via The Motley Fool

Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug ↗

February 27, 2024

Both companies are working on treatments for genetic disorders.

Via Investor's Business Daily

3 Biotech Stocks Bound to Blast Off By 2029 ↗

February 27, 2024

Biotech stocks are risky, but rewarding. These three biotechs specifically could see exponential gains in the coming years.

Via InvestorPlace

bluebird bio: How to play LEAPS options for growth and income

February 27, 2024

Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT

Via MarketBeat

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow ↗

February 27, 2024

Vertex shares have climbed almost 50% over the past year.

Via The Motley Fool

Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices ↗

February 26, 2024

Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.

Via Benzinga

3 Biotech Stocks to Buy and Hold for the Next 10 Years ↗

February 26, 2024

There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon.

Via The Motley Fool

Is CRISPR Therapeutics the NVIDIA of gene editing?

February 26, 2024

CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv

Via MarketBeat

Topics Artificial Intelligence

Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold ↗

February 26, 2024

Buy this stock if you're daring, but avoid it for now if you aren't.

Via The Motley Fool

Three S&P 500 Giants Lead This List Of Stocks Near Buy Points ↗

February 24, 2024

Watch these five stocks, but the market is slightly extended.

Via Investor's Business Daily

Topics Stocks

Stock Market Rallies To Record High On Nvidia: Weekly Review ↗

February 23, 2024

The stock market rally pulled back to start the week, but roared higher as booming Nvidia earnings and guidance fueled big AI-led gains. The S&P 500 and Dow Jones hit... Read More

Via Investor's Business Daily

Topics Stocks

Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗

February 22, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Crispr Reports Its First Profit In 10 Quarters, And Shares Fly Out Of A Buy Zone ↗

February 21, 2024

The company recently gained approval in the U.S. and abroad for its first gene-editing drug.

Via Investor's Business Daily

Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought ↗

February 20, 2024

These exciting players could deliver explosive growth over time.

Via The Motley Fool

If You Invested $10,000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Today ↗

February 19, 2024

It would have been a great move.

Via The Motley Fool

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.